

CLAIMS

1. An anti-PCI antibody, having at least any one of: (a) activity to inhibit an inhibitory effect of Protein C inhibitor (PCI) on activated Protein C (aPC) activity, or (b) activity to inhibit an inhibitory effect of Protein C inhibitor (PCI) on the production of activated Protein C (aPC) by thrombin /thrombomodulin (Thr/TM) complex.

2. An anti-PCI antibody, having both (a) activity to inhibit an inhibitory effect of Protein C inhibitor (PCI) on activated Protein C (aPC) activity, and (b) activity to inhibit an inhibitory effect of Protein C inhibitor (PCI) on the production of activated Protein C (aPC) by thrombin /thrombomodulin (Thr/TM) complex.

3. The antibody of claim 1 or 2, wherein the antibody competes for the antibody-binding site with an antibody comprising a variable region of an antibody selected from the group consisting of PC19G8, PC23A7, PC23D8, PC30G1, PC31E2, PC31F1, and PC39C6.

4. The antibody of claim 1 or 2, wherein the antibody comprises complementarity determining regions consisting of the amino acid sequences of any one of (a) to (f), or complementarity determining regions functionally equivalent thereto:

- (a) the amino acid sequences of SEQ ID NOs: 49, 50, and 51;
- (b) the amino acid sequences of SEQ ID NOs: 55, 56, and 57;
- (c) the amino acid sequences of SEQ ID NOs: 52, 53, and 54;
- (d) the amino acid sequences of SEQ ID NOs: 58, 59, and 60;
- (e) the amino acid sequence of SEQ ID NOs: 25, 31, and 36; and
- (f) the amino acid sequences of SEQ ID NOs: 41, 45, and 48.

5. The antibody of claim 1 or 2, wherein the antibody is selected from the group consisting of human antibodies, humanized antibodies, chimeric antibodies, antibody fragments, single-chain antibodies, and diabodies.

6. A composition comprising the antibody of claim 1 or 2 and a pharmaceutically acceptable carrier.

7. The composition of claim 6, further comprising Protein C and/or activated Protein C.

8. The composition of claim 6, wherein the composition is a pharmaceutical

composition used to prevent or treat a disease that has developed and/or advanced due to a decrease or deficiency of activated Protein C activity.

5 9. The composition of claim 8, wherein the disease is caused by hypercoagulation and/or a hyperinflammatory reaction.

10 10. The composition of claim 9, wherein the disease caused by hypercoagulation and/or a hyperinflammatory reaction is selected from the group consisting of sepsis, disseminated intravascular coagulation syndrome, arterial thrombosis, and venous thrombosis.

15 11. A method for preventing or treating a disease that has developed and/or advanced due to a decrease or deficiency of activated Protein C activity, wherein the method comprises the step of administering (a) Protein C and/or activated Protein C, and (b) the antibody of claim 1 or 2.

20 12. A method for preventing or treating a disease that has developed and/or advanced due to a decrease or deficiency of activated Protein C activity, wherein the method comprises the step of administering the antibody of claim 1 or 2.

25 13. A kit used to prevent or treat a disease that has developed and/or advanced due to a decrease or deficiency of activated Protein C activity, wherein the kit comprises (a) the antibody of claim 1 or 2, and (b) Protein C, activated Protein C, or both.

30 14. A kit used to prevent or treat a disease that has developed and/or advanced due to a decrease or deficiency of activated Protein C activity, wherein the kit comprises (a) Protein C, activated Protein C, and the antibody of claim 1 or 2; (b) a recording medium comprising a description on the combined use of (i) a therapeutically effective amount of Protein C and/or activated Protein C and (ii) the antibody of claim 1 or 2, or a link to the description.